



# **Summary of the Technical Background Report for the Proposed Maximum Contaminant Levels and Ambient Groundwater Quality Standards for PFOA, PFOS, PFNA and PFHxS.**

Stakeholder Meeting  
07/09/2019

# Presentation Overview

1. **Health-Based Risk Assessment Process**
2. **Chemical-Specific Reference Doses for:**  
    **PFOA    PFOS**  
    **PFNA    PFHxS**
3. **Exposure Assumptions**  
    **Use of the “Minnesota” Model**  
    **Relative Source Contribution**
4. **Modeled Exposures & Proposed MCLs**
5. **Questions**





## Acknowledgements

The New Hampshire Department of Environmental Services (NHDES) acknowledges the following groups for technical comments submitted by New Hampshire's:

- **residents and community stakeholders,**
- **academic institutions,**
- **community advocacy groups,**
- **representatives for the business community,**
- **and municipalities.**

Additionally, NHDES acknowledges the productive and professional discussions and information sharing by the following entities:

- **Connecticut Department of Public Health (CTDPH)**
- **Environmental Council of the States (ECOS) PFAS Caucus**
- **Federal-State Toxicology & Risk Analysis Committee (FSTRAC)**
- **Interstate Technology & Regulatory Council (ITRC) PFAS Working Group**
- **Massachusetts Department of Environmental Protection (MADEP)**
- **Michigan Department of Health & Human Services (MIDHHS)**
- **Minnesota Department of Health (MDH)**
- **New England Interstate Water Pollution Control Commission (NEIWPCC)**
- **New Jersey Department of Environmental Protection (NJDEP)**
- **Northeast Waste Management Officials' Association (NEWMOA)**



# Health-Based Risk Assessment Process

## 1. Identify the chemicals of concern:

Perfluorooctanoic acid (PFOA)

Perflurononanoic acid (PFNA)

Perfluorooctane sulfonic acid (PFOS)

Perfluorohexane sulfonic acid (PFHxS)


## 2. Identify sensitive and human-relevant health effects due to exposure to the chemical, and **derive a reference dose (RfD)** for the effects.

- Is the chemical a carcinogen?
- Are non-cancer health effects more protective than cancer endpoints?
- Do epidemiological studies provide clear evidence?
- Are there appropriate animal models for quantifying toxicity?

## 3. **Characterize an exposure scenario** using protective assumptions to determine an environmental concentration (*i.e.*, drinking water level) that will not exceed the RfD.

## Health-Based Risk Assessment Process

Per the CDC's **Agency for Toxic Substances and Disease Registry (ATSDR)** draft toxicity profile on PFAS (ATSDR, 2018), suspected health outcomes include:



## Health-Based Risk Assessment Process

### Proposed MCLs based on non-cancer endpoints


Specific PFAS	NHDES Revised MCLs	Animal Health Outcome
PFOA	12 ng/L	Liver toxicity & altered lipid metabolism
PFOS	15 ng/L	Suppressed immune response to vaccines
PFHxS	18 ng/L	Reduced female fertility
PFNA	11 ng/L	Liver toxicity & altered lipid metabolism

## Chemical-Specific Reference Doses

A **reference dose (RfD)** is:

“An estimate (with uncertainty spanning perhaps an order of magnitude) of a daily oral exposure to the human population (including sensitive subgroups) that is likely to be without an appreciable risk of deleterious effects during a lifetime.” – EPA 2002

RfDs are not synonymous to ATSDR minimal risk levels (MRLs).



## Chemical-Specific Reference Doses

Animal studies selected for RfDs in the Initial (January) MCL proposal.

Specific PFAS	Animal Study Health Effect	Notes & Corresponding Animal Serum Concentration
<b>Perfluorooctanoic acid (PFOA)</b>	Increased relative liver weight	Male mouse study Duration: 14 days 4,351 ng/mL BMDL <sub>10</sub> ; Loveless et al. 2006, NJDWQI 2017
<b>Perfluorooctane sulfonic acid (PFOS)</b>	Delayed pup growth & development	Reproductive & transgenerational rat study Duration: 2 generations 6,260 ng/mL Modeled; Luebker 2005ab, EPA 2016
<b>Perfluorohexane sulfonic acid (PFHxS)</b>	Reduced litter size	Reproductive & developmental CD-1 mouse study Duration: 14 days prior to & through gestation 27,200 ng/mL NOAEL; Chang et al. 2018
<b>Perfluorononanoic acid (PFNA)</b>	Increased relative liver weight	Reproductive & developmental CD-1 mouse study Duration: through gestation, 17 days 4,900 ng/mL BMDL <sub>10</sub> ; Das et al. 2015, NJDWQI 2018



## Perfluorooctanoic acid (PFOA) RfD Derivation

### Animal Starting Point (Internal Dose and Effect)

**Animal Serum Level**  
**(Benchmark Model, NJDWQI calculation)**



Increased relative liver weight,  
or the onset of hepatotoxicity

4,351 ng/mL

### Uncertainty Factors

<b>Human-to-Human Variation</b>	10
<b>Rodent versus Human Sensitivity</b> (assumes humans are more sensitive than mice)	$10^{0.5}$
<b>Database Uncertainty</b> (suspected growth & immune effects)	$\times 10^{0.5}$
<b>Total Uncertainty Factor</b>	100

**Internal Target Serum Level**



4,351 ng/mL  
÷ 100  
43.5 ng/mL

### Estimation of Human External Dose

#### Dosimetric Adjustment Factor (DAF)

Converts the internal blood dose (above) to an external (oral) dose of the chemical.

$$DAF = V_d \times \left( \frac{\ln 2}{\text{Half-life (days)}} \right)$$

$$DAF = 0.17 \text{ L/kg} \times \left( \frac{\ln 2}{840 \text{ days}} \right) = 1.40 \times 10^{-4} \text{ L/kg-d}$$

Assumed a **2.3 year half-life**

$$\begin{array}{r} 43.5 \text{ ng/mL} \\ 1.40 \times 10^{-4} \text{ L/kg-d} \\ \times \quad 1,000 \text{ mL/L} \\ \hline 6.1 \text{ ng/kg-d} \end{array}$$

**PFOA RfD, 6.1 ng/kg-d**



## Perfluorooctane sulfonic acid (PFOS) RfD Derivation

### Animal Starting Point (Internal Dose and Effect)

**Animal Serum Level**  
(No Observed Adverse Effect Level,  
Agreed with MDH 2019 Assessment)



Decreased immunoglobulin production,  
Or reduced vaccine response

2,360 ng/mL

### Uncertainty Factors

Human-to-Human Variation	10
Rodent versus Human Sensitivity (assumes humans are more sensitive than mice)	$10^{0.5}$
<b>Database Uncertainty</b> (suspected growth & fetal thyroid effects)	$\times 10^{0.5}$
<b>Total Uncertainty Factor</b>	100

### Internal Target Serum Level



$$\frac{2,360 \text{ ng/mL}}{100} = 23.6 \text{ ng/mL}$$

### Estimation of Human External Dose

#### Dosimetric Adjustment Factor (DAF)

Converts the internal blood dose (above) to an external (oral) dose of the chemical.

$$\text{DAF} = V_d \times \left( \frac{\text{Ln}2}{\text{Half-life (days)}} \right)$$

$$\text{DAF} = 0.23 \text{ L/kg} \times \left( \frac{\text{Ln}2}{1,241 \text{ days}} \right) = 1.28 \times 10^{-4} \text{ L/kg-d}$$

Assumed a 3.4 year half-life

$$\begin{array}{r} 23.6 \text{ ng/mL} \\ 1.28 \times 10^{-4} \text{ L/kg-d} \\ \times \quad 1,000 \text{ mL/L} \\ \hline 3.0 \text{ ng/kg-d} \end{array}$$

**PFOS RfD, 3.0 ng/kg-d**



## Perfluorononanoic acid (PFNA) RfD Derivation

### Animal Starting Point (Internal Dose and Effect)

**Animal Serum Level**  
**(Benchmark Model, NJDWQI calculation)**



Increased relative liver weight,  
or the onset of hepatotoxicity

4,900 ng/mL

### Uncertainty Factors

**Human-to-Human Variation** 10  
**Rodent versus Human Sensitivity**  $10^{0.5}$   
(assumes humans are more sensitive than mice)

**Database Uncertainty**  
(lack of multigenerational studies)  $\times 10^{0.5}$   
**Total Uncertainty Factor** 100

**Internal Target Serum Level**  $\longrightarrow$

4,900 ng/mL  
 $\div$  100  
49.0 ng/mL

### Estimation of Human External Dose

#### Dosimetric Adjustment Factor (DAF)

Converts the internal blood dose (above) to an external (oral) dose of the chemical.

$$DAF = V_d \times \left( \frac{\ln 2}{\text{Half-life (days)}} \right)$$

$$DAF = 0.20 \text{ L/kg} \times \left( \frac{\ln 2}{1,570 \text{ days}} \right) = 8.83 \times 10^{-5} \text{ L/kg-d}$$

Assumed a **4.3 year half-life**

$$\begin{array}{r} 49.0 \text{ ng/mL} \\ 8.83 \times 10^{-5} \text{ L/kg-d} \\ \times \quad 1,000 \text{ mL/L} \\ \hline 4.3 \text{ ng/kg-d} \end{array}$$

**PFNA RfD, 4.3 ng/kg-d**



## Perfluorohexane sulfonic acid (PFHxS) RfD Derivation

### Animal Starting Point (Internal Dose and Effect)

Animal Serum Level  
(Benchmark Model, *under peer-review*)



Reduced litter size in female mice,

13,900 ng/mL

### Uncertainty Factors

Human-to-Human Variation	10
Rodent versus Human Sensitivity (assumes humans are more sensitive than mice)	$10^{0.5}$
Duration of Exposure (14-day effect)	$10^{0.5}$
Database Uncertainty (lack of studies, fetal thyroid effects)	$\times 10^{0.5}$
Total Uncertainty Factor	300

Internal Target Serum Level

$$\begin{array}{r} 13,900 \text{ ng/mL} \\ \div 300 \\ \hline 46.3 \text{ ng/mL} \end{array}$$

### Estimation of Human External Dose

#### Dosimetric Adjustment Factor (DAF)

Converts the internal blood dose (above) to an external (oral) dose of the chemical.

$$\text{DAF} = \text{Vd} \times \left( \frac{\text{Ln2}}{\text{Halflife (days)}} \right)$$

$$\text{DAF} = 0.213 \text{ L/kg} \times \left( \frac{\text{Ln2}}{1,716 \text{ days}} \right) = 8.61 \times 10^{-5} \text{ L/kg-d}$$

Assumed a 4.7 year half-life

$$\begin{array}{r} 46.3 \text{ ng/mL} \\ 8.61 \times 10^{-5} \text{ L/kg-d} \\ \times 1,000 \text{ mL/L} \\ \hline 4.0 \text{ ng/kg-d} \end{array}$$

PFHxS RfD, 4.0 ng/kg-d



## Comparison of Reference Doses

RfDs for the four evaluated PFAS in comparison to values from other agencies.  
All values below are presented in **ng/kg-d**

Specific PFAS	NHDES (01/2019) (RfD)	NHDES (06/2019) (RfD)	US EPA 2016 (RfD)	ATSDR 2018 (MRL)	EFSA 2019 (RfD)
<b>PFOA</b>	5.2	<b>6.1</b>	20	3.0	0.8
<b>PFOS</b>	8.0	<b>3.0</b>	20	2.0	1.8
<b>PFHxS</b>	9.3	<b>4.0</b>	-	20	-
<b>PFNA</b>	2.5	<b>4.3</b>	-	3.0	-

USEPA. 2016. Drinking Water Advisory for Perfluorooctanoic acid (PFOA).

USEPA. 2016. Drinking Water Advisory for Perfluorooctane sulfonic acid (PFOS).

ASTDR. 2018. Toxicological Profile for Perfluoroalkyls Draft for Public Comment. <https://www.atsdr.cdc.gov/toxprofiles/tp.asp?id=1117&tid=237>

EFSA.

## Exposure Assumptions

Exposure characterization considers how much PFAS is permissible given:

1. Protective assumptions about drinking water ingestion rates
2. Estimation of other non-drinking water sources of exposure.

The U.S. EPA (2016) assumed the drinking water ingestion rate of the 90<sup>th</sup> percentile of lactating women, and that 20% of exposure is permissible through drinking water (PFOA & PFOS at 70 ng/L).

These assumptions vary by state agencies, sometimes resulting in different drinking water values despite similar RfDs.



## Exposure Assumptions: Initial Proposal (January 4<sup>th</sup>, 2019)

$$\frac{\text{RfD (ng/kg-day)} \times \text{Relative Source Contribution (\%)}}{\text{Water Ingestion Rate (L/kg-day)}} = \text{Maximum Contaminant Level (ng/L)}$$

Specific PFAS	Reference Dose (ng/kg-day)	Water Ingestion Rate (L/kg-day)	Relative Source Contribution	Proposed MCL (ng/L)
PFOA	These values changed in response to technical comments	These values changed in the EPA Exposure Factor Handbook (Feb 2019)	These values changed in response to technical comments	38
PFOS				70
PFHxS				85
PFNA				23

## Exposure Assumptions: **Example using June 2019 proposal**


$$\frac{\text{RfD (ng/kg-day)} \times \text{Relative Source Contribution (\%)}}{\text{Water Ingestion Rate (L/kg-day)}} = \text{Maximum Contaminant Level (ng/L)}$$

Specific PFAS	Reference Dose (ng/kg-day)	Water Ingestion Rate (L/kg-day)	Relative Source Contribution	<u>Example</u> Drinking Water Value (ng/L)
PFOA	6.1	These values do not account for the transfer of PFAS across the placenta and into breastmilk.	50%	These values would result in unacceptable serum levels in breastfed infants.
PFOS	3.0		50%	
PFHxS	4.0		50%	
PFNA	4.3		50%	



# Exposure Assumptions: Minnesota Model

## What is the Transgenerational (or Minnesota) Model?



The conceptual diagram for the toxicokinetic model.

Image from: Goeden et al. (2019), *Journal of Exposure Science & Environmental Epidemiology* vol. 29, 183–195.

Excel-based model is available upon request from Minnesota Department of Health.

## Human Half-life Assumptions

- NHDES applied **average (central tendency)** half-life estimates for PFOA (2.3 years), PFOS (3.4 years), PFNA (4.3 years) and PFHxS (4.7 years).
- NHDES did not apply the 95<sup>th</sup> percentile, or other high-end values derived from occupational exposures.

## Placental & breastmilk transfer efficiencies

- NHDES applied **average (central tendency)** transfer efficiencies, similar to MDH and MIDHHS.

## Duration of *exclusive* breastfeeding

- NHDES applied a **conservative 12-month exclusive breastfeeding duration** for the modeled exposure scenarios.


## Breastmilk & water ingestion rates

- NHDES applied the **95<sup>th</sup> percentile (conservative)** ingestion rates for water and breastmilk across life.

Values are summarized in Table 3 of the June Report. 17

# Exposure Assumptions: Minnesota Model


## What is the Transgenerational (or Minnesota) Model?



The model allows for the comparison of:

- **predicted blood levels (left y-axis)** to
- **the % of allowable maximum dose (right y-axis).**

Example model output for a PFOA MCL of 12 ng/L using NHDES's risk assessment assumptions.



The conceptual diagram for the toxicokinetic model.

Image from: Goeden et al. (2019), *Journal of Exposure Science & Environmental Epidemiology* vol. 29, 183–195.


Excel-based model is available upon request from Minnesota Department of Health.

## Exposure Assumptions: Relative Source Contribution

This is **how we “budget” the daily dose (RfD)** for water versus non-drinking water sources of exposure.

- **20%** - Low and the default EPA recommendation when “we don’t know”. Results in the most restrictive MCL.
- **50%** - Consistent with values derived from NHANES to estimate background
- **80%** - Results in a higher MCL value and assumes that other sources are not contributing to exposure (20% or less).

**Relative Source Contribution**  
(example below for visualization purposes)



## Exposure Assumptions: Relative Source Contribution

20%

### U.S. EPA (2016)

- **20% RSC for PFOA & PFOS** for the lifetime health advisory of 70 ng/L, based on RfDs of 20 ng/kg-d.

### Vermont - VTDOH (2016-2017)

- **20% RSC across all** for health-based screening values (HBSVs).

### New Jersey - NJDWQI (2017-2018)

- **20% RSC for PFOA & PFOS** because of insufficient serum data (proposed MCL).
- **50% RSC for PFNA** because of sufficient serum data from NHANES and a NJ community (MCL).

### New York - NYDWQC (2018)

- **≤60% RSC for PFOA & PFOS** recommendation based on serum data (proposed MCL).

### Minnesota - MDH (2017-2019)

- **50% RSC for PFOA, PFOS & PFHxS** in their model for (HBSVs).

### Michigan - MIDHHS (2019)

- **50% RSC for PFOA, PFOS, PFNA & PFHxS** in MDH's transgenerational model (HBSVs).

How did the NHDES MCLs arrive at a 50% RSC?


# Exposure Assumptions: Relative Source Contribution

NHDES referred to the EPA Decision Tree for determining the relative source contribution.

Arrived at a **50% ceiling** combined with apportionment (**subtraction method**) to derive chemical specific RSCs.

US EPA. 2000. Methodology for Deriving Ambient Water Quality Criteria for the Protection of Human Health (2000) Documents.

Accessed online at: <https://www.epa.gov/wqc/methodology-deriving-ambient-water-quality-criteria-protection-human-health-2000-documents>





## Exposure Assumptions: Relative Source Contribution

In the initial proposal, NHDES estimated “background” using existing blood data. However, this value should reflect the typical non-drinking water exposures.

Used the EPA subtraction method:

$$\frac{\text{Target serum level (ng/mL)} - \text{Population background (ng/mL)}}{\text{Target serum level (ng/mL)}} = \text{RSC}$$

Using the NHANES (**average**) for PFOA:

$$\frac{43.5 \text{ ng/L} - 1.8 \text{ ng/L}}{43.5 \text{ ng/L}} = 0.96 \text{ or } 96\%$$

Using Adults from Southern NH (**95<sup>th</sup> percentile**) for PFOA:

$$\frac{43.5 \text{ ng/L} - 26.6 \text{ ng/L}}{43.5 \text{ ng/L}} = 0.39 \text{ or } 39\%$$

The use of the **NH-specific data likely overestimates** the background (non-drinking water) exposure.

But, the current lack of regulations on PFAS means an 80% RSC, especially for adults, is inadequately protective.

# Exposure Assumptions: Relative Source Contribution

## Estimation of RSC by Subtraction Method Using NH-specific data


Subtraction method applied to all 4 PFAS using blood data collected by NH Dept. Health & Human Services from highest exposed populations.

Used NH-specific PFAS blood concentrations:

	<u>Geometric mean</u>	<u>95<sup>th</sup> Percentile</u>
<b>PFOA*</b>	4.40 ng/mL	<b>26.6 ng/mL</b>
<b>PFOS**</b>	10.2 ng/mL	<b>31.7 ng/mL</b>
<b>PFHxS**</b>	4.50 ng/mL	<b>26.0 ng/mL</b>
<b>PFNA</b>	0.66 ng/mL	<b>1.70 ng/mL</b>

\* **PFOA** concentrations from exposed population in Merrimack (217 participants) & Southern NH (219 participants).

\*\* **PFOS & PFHxS** concentrations from exposed population in Pease, NH (256 participants).





## Exposure Assumptions: Relative Source Contribution

### Estimation of RSC Using NHANES data

RSC estimates using the NHANES 2013-2014 dataset (summarized by Daly et al. 2018):

- **geometric mean (GM) and**
- **95<sup>th</sup> percentile.**

NHANES data more likely to reflect background exposure levels from non-drinking water sources.

Reference Population	Reference Serum level (ng/mL)	Target Serum Level (ng/mL)	Resulting RSC Allotment for Drinking Water (%)
<b>PFOA</b>			
3-5 year olds (GM)	2.00	43.5	<b>95.4</b>
6-11 year olds (GM)	1.89	43.5	<b>95.7</b>
12-19 year olds (GM)	1.66	43.5	<b>96.2</b>
3-5 year olds (95 <sup>th</sup> percentile)	5.58	43.5	<b>87.2</b>
6-11 year olds (95 <sup>th</sup> percentile)	3.84	43.5	<b>91.2</b>
12-19 year olds (95 <sup>th</sup> percentile)	3.47	43.5	<b>92.0</b>
<b>PFOS</b>			
3-5 year olds (GM)	3.38	24.0	<b>85.9</b>
6-11 year olds (GM)	4.15	24.0	<b>82.7</b>
12-19 year olds (GM)	3.54	24.0	<b>85.3</b>
3-5 year olds (95 <sup>th</sup> percentile)	8.82	24.0	<b>63.3</b>
6-11 year olds (95 <sup>th</sup> percentile)	12.40	24.0	<b>48.3</b>
12-19 year olds (95 <sup>th</sup> percentile)	9.30	24.0	<b>61.3</b>
<b>PFNA</b>			
3-5 year olds (GM)	0.76	49.0	<b>98.4</b>
6-11 year olds (GM)	0.81	49.0	<b>98.3</b>
12-19 year olds (GM)	0.60	49.0	<b>98.8</b>
3-5 year olds (95 <sup>th</sup> percentile)	3.49	49.0	<b>92.9</b>
6-11 year olds (95 <sup>th</sup> percentile)	3.19	49.0	<b>93.5</b>
12-19 year olds (95 <sup>th</sup> percentile)	2.00	49.0	<b>95.9</b>
<b>PFHxS</b>			
3-5 year olds (GM)	0.72	46.3	<b>98.4</b>
6-11 year olds (GM)	0.91	46.3	<b>98.0</b>
12-19 year olds (GM)	1.27	46.3	<b>97.3</b>
3-5 year olds (95 <sup>th</sup> percentile)	1.62	46.3	<b>96.5</b>
6-11 year olds (95 <sup>th</sup> percentile)	4.14	46.3	<b>91.1</b>
12-19 year olds (95 <sup>th</sup> percentile)	6.30	46.3	<b>86.4</b>



## Modeled Exposures & Proposed MCLs


Given these **reference doses** and **exposure assumptions**, the proposed MCLs/AGQS are:

PFOA	12 ng/L
PFOS	15 ng/L
PFHxS	18 ng/L
PFNA	11 ng/L

Because of the unique properties of PFAS, accounting for breastmilk transfer is necessary.

The 50% RSC (upper limit) protects children from additional exposures to from other non-drinking water sources of PFAS.

**Thus, these proposed MCLs are protective across all life stages for associated chronic health outcomes.**



## Modeled Exposures & Proposed MCLs

Where was NHDES conservative in its health-based risk assessment?

Central Tendency Assumptions	Conservative (High-End) Assumptions
<ol style="list-style-type: none"><li>1. Application of Uncertainty Factors (see page 23 of the June Technical Report)</li><li>2. Human half-life estimates (average values)</li><li>3. Placental &amp; breastmilk transfer estimates (average values)</li><li>4. Individual MCLs specific to each compound instead of a class-based MCL.</li><li>5. Relative Source Contribution cap of 50%*</li></ol>	<ol style="list-style-type: none"><li>1. Accounting for breastmilk &amp; placental transfer in a drinking water standard (MDH model)</li><li>2. 95<sup>th</sup> percentile water consumptions rates, <i>throughout life</i></li><li>3. Assumed 12-month exclusive breastfeeding period</li><li>4. Assuming 100% absorption in GI tract</li><li>5. Relative Source Contribution cap of 50%*</li></ol>


## Modeled Exposures & Proposed MCLs

Given these **reference doses** and **exposure assumptions**, the proposed MCLs/AGQS are:

PFOA	12 ng/L
PFOS	15 ng/L
PFHxS	18 ng/L
PFNA	11 ng/L

NHDES is *currently* not recommending a class- or subclass-based approach to regulating PFAS.

NHDES is committed to continuing to review the scientific literature for advances in risk assessment for these and other PFAS.



# Questions

References and Supporting Documents can be found in the Reference List of the June 2019 Technical Report:

<https://www.des.nh.gov/organization/commissioner/legal/rulemaking/documents/pfas-scr-attch-1-w-ltr.pdf>

Technical Questions about this presentation can be submitted to the **NHDES Permitting & Environmental Health Bureau**:

**Jonathan Ali, Ph.D.**

Toxicologist

Phone: (603) 271-1359

Email: [jonathan.ali@des.nh.gov](mailto:jonathan.ali@des.nh.gov)

**Mary Butow, M.S.**

Human Health Risk Assessor

Phone: (603) 271-8693

Email: [mary.butow@des.nh.gov](mailto:mary.butow@des.nh.gov)

**David Gordon, M.S.**

Human Health Risk Assessor

Phone: (603) 271-4608

Email: [david.gordon@des.nh.gov](mailto:david.gordon@des.nh.gov)

## ATTACHMENT 1

New Hampshire Department of Environmental Services

Technical Background Report for the June 2019 Proposed Maximum Contaminant Levels (MCLs) and Ambient Groundwater Quality Standards (AGQSS) for Perfluorooctane sulfonic Acid (PFOS), Perfluorooctanoic Acid (PFOA), Perfluorononanoic Acid (PFNA), and Perfluorohexane sulfonic Acid (PFHxS)

And

Letter from Dr. Stephen M. Roberts, Ph.D. dated 6/25/2019 – Findings of Peer Review Conducted on Technical Background Report

June 28, 2019